Derek Archila
Stock Analyst at Wells Fargo
(4.37)
# 337
Out of 5,154 analysts
228
Total ratings
53.75%
Success rate
16.96%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEPN Septerna | Maintains: Overweight | $28 → $48 | $28.78 | +66.78% | 6 | Mar 3, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $78 → $79 | $61.18 | +29.13% | 3 | Mar 2, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $1,317 → $1,247 | $717.79 | +73.73% | 16 | Feb 27, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $114 → $110 | $39.68 | +177.22% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $145 → $136 | $93.52 | +45.42% | 8 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $88 → $98 | $65.36 | +49.94% | 3 | Feb 13, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $107 → $101 | $95.94 | +5.27% | 13 | Feb 11, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $26 → $29 | $28.34 | +2.33% | 3 | Feb 3, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $30 → $29 | $15.10 | +92.05% | 8 | Jan 29, 2026 | |
| ASND Ascendis Pharma | Maintains: Overweight | $322 → $330 | $240.65 | +37.13% | 16 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $26 | $20.07 | +29.55% | 14 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $479 → $376 | $320.66 | +17.26% | 2 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $30 | $17.80 | +68.54% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $39 | $26.90 | +44.98% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $33 | $8.10 | +307.41% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $116 | $83.49 | +38.94% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $25 | $13.71 | +82.35% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $5.16 | +423.26% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $13.60 | +10.29% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $55.41 | +46.18% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $41.55 | -27.79% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.95 | -28.06% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $3.04 | +228.95% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.82 | +21.36% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $29.43 | +29.12% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $25.29 | +18.62% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $3.17 | -36.91% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $2.30 | +117.86% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $4.70 | +219.15% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $24.08 | -41.86% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $26.66 | +68.79% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.72 | +635.29% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.13 | +193.64% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $32.92 | +486.27% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $86.93 | -52.84% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $14.06 | +1,037.98% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $21.87 | +174.35% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $7.89 | +267.55% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $0.97 | +5,072.77% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $20.46 | +149.27% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $10.72 | +720.90% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $22.00 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $31.05 | - | 2 | Aug 3, 2017 |
Septerna
Mar 3, 2026
Maintains: Overweight
Price Target: $28 → $48
Current: $28.78
Upside: +66.78%
Disc Medicine
Mar 2, 2026
Maintains: Overweight
Price Target: $78 → $79
Current: $61.18
Upside: +29.13%
argenx SE
Feb 27, 2026
Maintains: Overweight
Price Target: $1,317 → $1,247
Current: $717.79
Upside: +73.73%
Soleno Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $114 → $110
Current: $39.68
Upside: +177.22%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $145 → $136
Current: $93.52
Upside: +45.42%
BridgeBio Pharma
Feb 13, 2026
Maintains: Overweight
Price Target: $88 → $98
Current: $65.36
Upside: +49.94%
Incyte
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $107 → $101
Current: $95.94
Upside: +5.27%
Viridian Therapeutics
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $28.34
Upside: +2.33%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $30 → $29
Current: $15.10
Upside: +92.05%
Ascendis Pharma
Jan 20, 2026
Maintains: Overweight
Price Target: $322 → $330
Current: $240.65
Upside: +37.13%
Jan 20, 2026
Maintains: Overweight
Price Target: $29 → $26
Current: $20.07
Upside: +29.55%
Jan 20, 2026
Maintains: Equal-Weight
Price Target: $479 → $376
Current: $320.66
Upside: +17.26%
Jan 8, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $17.80
Upside: +68.54%
Jan 6, 2026
Maintains: Overweight
Price Target: $17 → $39
Current: $26.90
Upside: +44.98%
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $8.10
Upside: +307.41%
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $83.49
Upside: +38.94%
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $13.71
Upside: +82.35%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $5.16
Upside: +423.26%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $13.60
Upside: +10.29%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $55.41
Upside: +46.18%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $41.55
Upside: -27.79%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.95
Upside: -28.06%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $3.04
Upside: +228.95%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.82
Upside: +21.36%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $29.43
Upside: +29.12%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $25.29
Upside: +18.62%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $3.17
Upside: -36.91%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $2.30
Upside: +117.86%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $4.70
Upside: +219.15%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $24.08
Upside: -41.86%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $26.66
Upside: +68.79%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.72
Upside: +635.29%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $6.13
Upside: +193.64%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $32.92
Upside: +486.27%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $86.93
Upside: -52.84%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $14.06
Upside: +1,037.98%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $21.87
Upside: +174.35%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $7.89
Upside: +267.55%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $0.97
Upside: +5,072.77%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $20.46
Upside: +149.27%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $10.72
Upside: +720.90%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $22.00
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $31.05
Upside: -